Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

ABSTRACT Of 393 isolates of Streptococcus pneumoniae from U.S. children collected in 2005-2006, nonvaccine serotypes accounted for 89.1%, with serotype 19A the most prevalent, representing 30.5% of all isolates. The MIC90 of faropenem against serotype 19A isolates was 1 μg/ml, compared to ≥8 μg/ml against amoxicillin/clavulanate, cefdinir, cefuroxime axetil, and azithromycin.

[1]  G. Noel,et al.  Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States , 2003, Antimicrobial Agents and Chemotherapy.

[2]  C. Whitney,et al.  Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. , 2005, The Journal of infectious diseases.

[3]  Steven Black,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The Journal of pediatrics.

[4]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[5]  D. Crook,et al.  Vaccine Escape Recombinants Emerge after Pneumococcal Vaccination in the United States , 2007, PLoS pathogens.

[6]  In Ho Park,et al.  Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae , 2007, Journal of Clinical Microbiology.

[7]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[8]  E. Alpern,et al.  Serotype prevalence of occult pneumococcal bacteremia. , 2001, Pediatrics.

[9]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[10]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[11]  M. O'riordan,et al.  Serogroup 19 Pneumococci Containing Both mef and erm Macrolide Resistance Determinants in an American City , 2006, The Pediatric infectious disease journal.

[12]  M. Pichichero,et al.  Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States , 2007, The Pediatric infectious disease journal.

[13]  L. Ednie,et al.  In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae , 2007, Antimicrobial Agents and Chemotherapy.

[14]  D. Musher.  Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Susan S. Huang,et al.  Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.

[16]  S. Kaplan,et al.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. , 2004, Pediatrics.

[17]  W. Schaffner,et al.  Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Schuchat,et al.  Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment , 2005, The Lancet.

[19]  S. Dowell,et al.  Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis , 2000, Pediatrics.

[20]  L. McGee.  The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae. , 2007, Current opinion in microbiology.

[21]  N. Janjić,et al.  National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study , 2007, Antimicrobial Agents and Chemotherapy.

[22]  W. Schaffner,et al.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. , 2006, The New England journal of medicine.

[23]  M. Pichichero,et al.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. , 2007, JAMA.

[24]  E. Lewis,et al.  Postlicensure Surveillance for Pneumococcal Invasive Disease After Use of Heptavalent Pneumococcal Conjugate Vaccine in Northern California Kaiser Permanente , 2004, The Pediatric infectious disease journal.

[25]  R. Breiman,et al.  Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. , 1995, The Journal of infectious diseases.

[26]  J. Karlowsky,et al.  Faropenem: review of a new oral penem , 2007, Expert review of anti-infective therapy.

[27]  M. Joloba,et al.  Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.